What's new in tocolytics.
Tocolytic therapy represents the final obstetric end point in the prevention of premature births. For the past two decades, betamimetic therapy has been the mainstay of tocolytic therapy. Newer agents, indomethacin and nifedipine, offer new hope in the treatment of premature labor. With the introduction of these newer agents, combination drug therapy appears to be on the horizon.
Department of Obstetrics and Gynecology, Wilford Hall USAF Medical Center, Lackland AFB, Texas.
M R
MR
Leonardi
G D
GD
Hankins
D000318:Adrenergic beta-Agonists / Q000494:pharmacology / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007752:Obstetric Labor, Premature / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D011247:Pregnancy; D015149:Tocolytic Agents / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*
D000318:Adrenergic beta-Agonists; D000900:Anti-Bacterial Agents; D002121:Calcium Channel Blockers; D016861:Cyclooxygenase Inhibitors; D015149:Tocolytic Agents